Genetic variants of STAT-4 affect the development of graft fibrosis after liver transplantation for HCV-induced liver disease

Transplantation

Volumn 95, Issue 1, 2013, Pages 203-208

  Eurich, Dennis ^a   Boas Knoop, Sabine ^a   Struecker, Benjamin ^a   Neuhaus, Ruth ^a   Neuhaus, Peter ^a   Bahra, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

genetic variants; HCV recurrence; STAT 4

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; RIBAVIRIN; STAT4 PROTEIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALLELE; ANTIVIRAL THERAPY; ARTICLE; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GRAFT DYSFUNCTION; GRAFT FIBROSIS; HEPATITIS C; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STAT4 GENE; TREATMENT OUTCOME;

ADULT; AGED; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; STAT4 TRANSCRIPTION FACTOR;

EID: 84872059385     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318277e2f6     Document Type: Article

References (48)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655.
2. Berenguer M. Recurrent allograft disease: viral hepatitis. Acta Gastroenterol Belg 2005; 68: 337.
3. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209.
4. Schuppan D, Krebs A, Bauer M, et al. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10(Suppl 1): S59.
5. Chambers JC, Zhang W, Sehmi J, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat Genet 2011; 43: 1131.
6. Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317.
7. Eurich D, Bahra M, Boas-Knoop S, et al. Transforming growth factor A-1 polymorphisms and graft fibrosis progression after liver transplantation for HCV-induced liver disease. Liver Transpl 2011; 17: 279.
8. do ON, Eurich D, Schmitz P, et al. A 7-gene signature of the recipient predicts the progression of fibrosis after liver transplantation for hepatitis C virus infection. Liver Transpl 2012; 18: 298.
9. Kong X, Horiguchi N, Mori M, et al. Cytokines and STATs in Liver Fibrosis. Front Physiol 2012; 3: 69.
10. Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005; 2: 92.
11. Wang H, Lafdil F, Kong X, et al. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci 2011; 7: 536.
12. Kato A, Graul-Layman A, Edwards MJ, et al. Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4. Transplantation 2002; 73: 1142.
13. Shen XD, Ke B, Zhai Y, et al. Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice: HO-1 dependence of Stat4 disruption-mediated cytoprotection. Hepatology 2003; 37: 296.
14. Mells GF, Floyd JA, Morley KI, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011; 43: 329.
15. Peng WJ, Pan HF, Tao JH, et al. A meta-analysis of the association between cytokine gene polymorphisms and systemic sclerosis. Mod Rheumatol 2012; 22: 695.
16. Liang YL, Wu H, Shen X, et al. Association of STAT4 rs7574865 polymorphism with autoimmune diseases: a meta-analysis. Mol Biol Rep 2012; 39: 8873.
17. Rueda B, Broen J, Simeon C, et al. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum Mol Genet 2009; 18: 2071.
18. Ben-Ari Z, Pappo O, Druzd T, et al. Role of cytokine gene polymorphism and hepatic transforming growth factor beta1 expression in recurrent hepatitis C after liver transplantation. Cytokine 2004; 27: 7.
19. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100.
20. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105.
21. Shackel NA, Jamias J, Rahman W, et al. Early high peak hepatitis C viral load levels independently predict hepatitis C-related liver failure post-liver transplantation. Liver Transpl 2009; 15: 709.
22. Roche B, Sebagh M, Canfora ML, et al. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766.
23. Fiore CE, Pennisi P, Tamborino C. YKL-40 and graft rejection. Am J Med 2000; 108: 688.
24. Iadonato SP, Katze MG. Genomics: Hepatitis C virus gets personal. Nature 2009; 461: 357.
25. Neff GW, O'Brien CB, Nery J, et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10: 1497.
26. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41: 830.
27. Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 2011; 17: 1394.
28. Asthana S, Toso C, Meeberg G, et al. The impact of sirolimus on hepatitis C recurrence after liver transplantation. Can J Gastroenterol 2011; 25: 28.
29. Lake JR. The role of immunosuppression in recurrence of hepatitis C. Liver Transpl 2003; 9: S63.
30. Wasmuth HE, Trautwein C. Prediction of fibrosis progression in hepatitis C infection: are genetics ready for clinical use? J Hepatol 2011; 55: 3.
31. Mas VR, Fisher RA, Maluf DG, et al. Polymorphisms in cytokines and growth factor genes and their association with acute rejection and recurrence of hepatitis C virus disease in liver transplantation. Clin Genet 2004; 65: 191.
32. Eurich D, Boas-Knoop S, Bahra M, et al. Role of IL28B polymorphism in the development of hepatitis C virus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation 2012; 93: 644.
33. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46: 297.
34. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50: 1038.
35. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704.
36. Pungpapong S, Nunes DP, Krishna M, et al. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Liver Transpl 2008; 14: 1294.
37. Neumann U, Puhl G, Bahra M, et al. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin. Transplantation 2006; 82: 43.
38. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958.
39. Eurich D, Boas-Knoop S, Yahyazadeh A, et al. Role of mannosebinding lectin-2 polymorphism in the development of acute cellular rejection after transplantation for hepatitis C virus-induced liver disease. Transpl Infect Dis 2012; 14: 488.
40. Yang H, Zhou Q, Chen ZM, et al. Polymorphisms in STAT4 increase the risk of acute renal allograft rejection in the Chinese population. Transpl Immunol 2011; 24: 216.
41. Eurich D, Boas-Knoop S, Ruehl M, et al. Relationship between interleukin-28b gene polymorphism and the histological severity of HCV-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl 2011; 17: 289.
42. Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577; e1571-1573.
43. Edlich B, Ahlenstiel G, Azpiroz AZ, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 2012; 55: 39.
44. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002; 8: S14.
45. Hove WR, van Hoek B, Bajema IM, et al. Extensive chimerism in liver transplants: vascular endothelium, bile duct epithelium, and hepatocytes. Liver Transpl 2003; 9: 552.
46. Moroso V, Metselaar HJ, Mancham S, et al. Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transpl 2010; 16: 895.
47. Goldin RD, Goldin JG, Burt AD, et al. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25: 649.
48. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513.